Press release
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Relapsed/Refractory Acute Myeloid Leukemia Overview
Relapsed/Refractory Acute Myeloid Leukemia Myeloid Leukemia which means the leukemia has come back after treatment and remission. Refractory AML means the leukemia did not respond to treatment. AML relapse affects about 50% of all patients who achieved remission after initial treatment, and can occur several months to several years after treatment. Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis and treatment remains challenging.
"Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market.
The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Relapsed/Refractory Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. Relapsed/Refractory Acute Myeloid Leukemia Key players such as - Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, Glyco Mimetics, AROG Pharmaceuticals, and others, are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment
• Relapsed/Refractory Acute Myeloid Leukemia Emerging therapies such as - CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others are expected to have a significant impact on the Relapsed/Refractory Acute Myeloid Leukemia market in the coming years.
• In January 2021 Apollomics and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML)
• In October 2021 Apollomics initiated a Phase III randomized, double-blinded bridging trial to evaluate the efficacy of Uproleselan administered with chemotherapy versus chemotherapy alone in chinese patients with Relapsed/Refractory Acute Myeloid Leukemia.
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Product Type
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Product Type
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Molecule Type
• Relapsed/Refractory Acute Myeloid Leukemia by Stage and Molecule Type
DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Get a Free Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
• CYAD-02: Celyad Oncology
• FHD-286: Foghorn Therapeutics
• AB8939: AB Science
• ONC201: Oncoceutics
• Sarclisa: Sanofi
• TCB008: TC Biopharm
• Keytruda: Merck & Co
• Uproleselan: Glyco Mimetics
• Crenolanib: AROG Pharmaceuticals
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis:
The Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
• Relapsed/Refractory Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Relapsed/Refractory Acute Myeloid Leukemia product details are provided in the report. Download the Relapsed/Refractory Acute Myeloid Leukemia pipeline report to learn more about the emerging Relapsed/Refractory Acute Myeloid Leukemia therapies at:
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Drivers
• Rising incidence of Acute Myeloid Leukemia
• Advancements in pharmacology and molecular biology to promote drug development
• Rising geriatric population
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Barriers
• High cost associated with the management of acute myeloid leukemia
• Side effects associated with the acute myeloid leukemia treatment
Scope of Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, Glyco Mimetics, AROG Pharmaceuticals, and others
• Key Relapsed/Refractory Acute Myeloid Leukemia Therapies: CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and Relapsed/Refractory Acute Myeloid Leukemia emerging therapies
• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Relapsed/Refractory Acute Myeloid Leukemia market drivers and Relapsed/Refractory Acute Myeloid Leukemia market barriers
Request for Sample PDF Report for Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Relapsed/Refractory Acute Myeloid Leukemia Report Introduction
2 Relapsed/Refractory Acute Myeloid Leukemia Executive Summary
3 Relapsed/Refractory Acute Myeloid Leukemia Overview
4 Relapsed/Refractory Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5 Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics
6 Relapsed/Refractory Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7 Relapsed/Refractory Acute Myeloid Leukemia Mid Stage Products (Phase II)
8 Relapsed/Refractory Acute Myeloid Leukemia Early Stage Products (Phase I)
9 Relapsed/Refractory Acute Myeloid Leukemia Preclinical Stage Products
10 Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Assessment
11 Relapsed/Refractory Acute Myeloid Leukemia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Relapsed/Refractory Acute Myeloid Leukemia Key Companies
14 Relapsed/Refractory Acute Myeloid Leukemia Key Products
15 Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
16 Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers
17 Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives and Conclusion
18 Relapsed/Refractory Acute Myeloid Leukemia Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia drugs and therapies- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Relapsed/Refractory Acute Myeloid Leukemia Market https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Relapsed/Refractory Acute Myeloid Leukemia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2912491 • Views: 88
More Releases from DelveInsight Business Research
Graves' Ophthalmopathy Market to witness growth by 2032, estimates DelveInsight …
DelveInsight's "Graves' Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graves' Ophthalmopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
To know more about the Graves' Ophthalmopathy market report offerings, click here: https://www.delveinsight.com/report-store/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Graves' Ophthalmopathy Market Key…
Anterior Uveitis Market to Witness Growth by 2032, Estimates DelveInsight | Nova …
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Anterior Uveitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Anterior Uveitis market size…
Postoperative Pain Pipeline Drugs Analysis Report, 2023: Clinical Trials, Therap …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Postoperative Pain pipeline constitutes 7+ key companies continuously working towards developing 8+ Postoperative Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Postoperative Pain Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Postoperative Pain Market.
The Postoperative Pain…
Myelofibrosis Pipeline Drugs Analysis Report, 2023: Clinical Trials, Therapies, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myelofibrosis pipeline constitutes 7+ key companies continuously working towards developing 8+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Myelofibrosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.
The Myelofibrosis Pipeline report embraces in-depth commercial…
More Releases for Myeloid
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.…
Acute Myeloid Leukemia Assessment and Therapeutics Pipeline Review 2018
Summary
Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy…
Acute Myeloid Leukemia Therapeutics Market : Global Snapshot by 2025
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. Leukemia can grow along either the myeloid or lymphoid stem cell lines, it…
EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026
EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026
Summary
Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women. AML progresses quickly, has low survival rates, and has high rates of relapse, even with treatment. The cause of AML is unknown, but an increased…
EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026
Albany, New York, July 28, 2017 : Recent research and the current scenario as well as future market potential of " Development of Acute Myeloid Leukemia - Epidemiology Forecast to 2026 : Trends and Application 2017 " globally.
Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men…
Develop business Strategies Of Acute Myeloid Leukemia Market 2024
"The Latest Research Report OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Acute Myeloid Leukemia Market
Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level…
